You are here

Impact of Affect Reactivity and Regulation on Breast Cancer Treatment Decisions

Workflow State: 
Approved
Type of proposal: 
Participant recruitment (what is this?)
Does this project have funding?: 
Yes

Researcher Information

First name: 
David
Last name: 
Spiegel
Degree: 
MD
Work phone number: 
(650) 723-8479

Institution Information

Stanford
401 Quarry Road, Room 2322
94305 Stanford , CA
United States

Project Information

List of Collaborators: 
Amit Etkin, M.D., Ph.D., Co-I Allison Kurian, M.D., Co-I James Gross, Ph.D, Co-I
Number of Participants Needed: 
200
Inclusion and Exclusion Criteria: 
Inclusion Criteria -- Women Diagnosed with breast cancer: 1.Female 2.Age 18 or older 3.Agree to suspend treatments containing Benzodiazepines and steroids up to 2 weeks pre and during cortisol sampling (based on PI’s clinical judgement) 4.Agree to taking saliva samples and having fMRI scan 5.No contraindications to MRI imaging (like ferromagnetic metal in their body) 6.Proficiency in English sufficient to complete questionnaires and follow instructions during the fMRI assessments 7.US Citizen or resident able to receive payment legally 8.Documented stage 0-III breast cancer 9.Unilateral breast tumors 10.Date of enrollment should not be more than 12 months from the date of breast cancer diagnosis. Enrollment before initial surgery is preferred but not required. Controls: 1.Female 2.Age 18 or older 3.Agree to suspend treatments containing Benzodiazepines and steroids up to 2 weeks pre and during cortisol sampling (based on PI’s clinical judgement) 4.Agree to having saliva samples and fMRI scan 5.No contraindications to MRI imaging (like ferromagnetic metal in their body) 6.Proficiency in English sufficient to complete questionnaires and follow instructions during the fMRI assessments 7.US Citizen or resident able to receive payment legally Exclusion Criteria -- Women Diagnosed with breast cancer: 1.Other active cancers within the past 10 years other than squamous cell carcinoma of the skin 2.Pregnant 3.Any significant neurologic disease, such as dementia, multi-infarct dementia, Parkinson's or Huntington’s disease, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, stroke, or traumatic brain injury 4.Hearing impaired 5.Current untreated psychosis, or bipolar disorder, or substance/alcohol abuse/dependence 6.Current use of psychotropic (based on PI’s clinical judgement) medication 5 or more days a week Controls: 1.Cancer diagnosis, current or past 2.Pregnant 3.Any significant neurologic disease, such as dementia, multi-infarct dementia, Parkinson's or Huntington’s disease, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, stroke, or traumatic brain injury 4.Hearing impaired 5.Current untreated psychosis, or bipolar disorder, or substance/alcohol abuse/dependence 6.Current use of psychotropic (based on PI’s clinical judgement) medication 5 or more days a week 7. Breast cancer diagnosis in 1 first degree relative or 2 or more second degree relatives 8.Ovarian cancer diagnosis in 1 first or second degree relative

Project Details

Primary Area of Study: 
IRB Approval: 
Yes
Legacy Date Received: 
2017-02-01 12:31:01